IMWG consensus on risk stratification in multiple myeloma
Because multiple myeloma presents as clinically and biologically heterogeneous, treatment and response outcomes vary.
Because treatment options have increased and will continue to do so, there must be a way to better understand the heterogeneity of the disease and apply this understanding to treatment regimens. Many prognostic markers have been identified, and it has been proposed to stratify patients into different risk groups based on these markers. In this consensus statement, the International Myeloma Working Group defines applicable risk categories based on current available information and “suggests the use of this set of prognostic factors as gold standards in all clinical trials” as well as to base further development “of more complex prognostic system or better prognostic factors.” These risk categories also “serve as a framework to rationalize the use of therapies.”
WJ Chng, A Dispenzieri, C-S Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, JS Miguel, P Sonneveld, M Cavo, S Usmani, Brian G.M. Durie, and H Avet-Loiseau on behalf of the International Myeloma Working Group
Click here to view article: